Connective Tissue Diseases


Products Article No. No. of tests
Varelisa ReCombi ANA Profile 184 96 10 Profiles


Antinuclear antibodies bind intracellular antigens and are serological hallmarks of systemic rheumatic diseases. In 1961 it was shown, that different immunofluorescence patterns correspond to different antibody specificities and thus sometimes to special diseases. In the ELISA, nuclear antigens can be used for the detection of those ANA specificities, which are of special interest for the diagnosis of rheumatic diseases.

Antigens in the Varelisa ReCombi ANA Profile:

dsDNA (recombinant plasmid double-stranded DNA)
U1RNP (human recombinant 70 kDa, A and C)

(synthetic SmD peptide)

SS-A/Ro (human recombinant 52 kD and 60 kD)

(human recombinant)

Scl-70 (human recombinant topoisomerase 1)
CENP (human recombinant CENP-B)
Jo-1 (human recombinant histidylt RNA synthetase)


Disease association, antibody prevalence and specificity


Disease and Prevalence

Clinical Significance


Active SLE with renal involvement: >95 %
without renal involvement: 50-70%
Inactive SLE: <40%

Specific marker in SLE; correlates with disease activity (monitoring), marker for tissue damage
dsDNA antibodies are associated with an increased risk of nephritis.
(70 kDa, A, C)
SLE: 30 - 40 %
MCTD: 100 %
U1 snRNP antibodies indicate a good prognosis concerning the development of renal involvement, also when they are found in combination with Sm.
MCTD is defined through high levels of anti-U1 snRNP.
Sm D SLE: 10 - 30 % Hihly specific marker for SLE 2
(52 kD, 60 kD)
SLE: 40 - 50 %
SS: 60 - 70 %
Mother of child with neonatal lupus
High risk of neonatal lupus if mother has SS-A/Ro (especially when directed to 52 kD) and SS-B/La antibodies 3
SS-B/La SLE: 5 - 10 %
SS: 25 - 50 %
Mother of child with neonatal lupus: 60%
SS-B/La antibodies are found almost always in combination with anti-SSA antibodies; more specific for Sjögren's syndrome than Anti-SS-A/Ro 3
Scl-70 Scleroderma:
20 - 60 %
Highly specific marker for scleroderma 3
CREST: 20-35 % Present in patients with scleroderma, in most cases the limited form. Also found in patients with primary biliary cirrhosis 3
Jo-1 Poly-/Dermatomyositis: 30 % Patients often have lung involvement. Jo-1 antibodies positive patients tend to have a severe disease with poor response to therapy 2


When is the measurement recommended?

Suspicion of connective tissue disease.

Antibody isotypes



  • Conrad K, Schössler W, Hiepe F (2002) Autoantibodies in Systemic Autoimmune Diseases. Pabst Science Publishers, Lengerich
  • Peter JB, Shoenfeld Y (1996) Autoantibodies. Elsevier Science B.V., Amsterdam
  • Shoenfeld Y, Gershwin ME, Meroni PL (2007) Autoantibodies, 2nd ed., Elsevier Science B.V., Amsterdam
  • Venrooij WJ, Maini RN (1996) Manual of Biological Markers of Disease. Kluwer Academic Publishers, Amsterdam
  • Peene I, Meheus L, Veys EM, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60, 1131-1136
  • Peng SL, Hardin JA, Craft J (1997) Antinuclear antibodies. In: Kelley WN (ed) Textbook of Rheumatology, pp 250-266. Saunders W.B., Philadelphia

Back to top